<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419887</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2109</org_study_id>
    <nct_id>NCT00419887</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel-Group, Ascending Single and Multiple Oral Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAF237 in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, effect of vildagliptin and
      how the body changes the blood level of vildagliptin of single and multiple oral doses of
      vildagliptin in healthy Chinese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single dose of vildagliptin in healthy Chinese volunteers at four sequentially ascending dose levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeated doses of vildagliptin in healthy Chinese volunteers at five sequentially ascending dose levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers at five sequentially ascending dose levels</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic/pharmacodynamic relationship in healthy Chinese volunteers</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin (LAF237)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese healthy volunteers age 18 to 45 years of age included

          -  In good health as confirmed by past medical history, physical examination,
             electrocardiogram, laboratory tests and urinalysis on the screening and baseline
             evaluation

          -  All subjects must have both parents of Chinese origin and citizenship and must have
             been born in China.

          -  Body mass index (BMI) within the range of 19 to 24 kg/m2 and weigh at least 50 kg

        Exclusion Criteria:

          -  Smokers

          -  Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter
             (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2)
             weeks prior to dosing. Paracetamol (or equivalent in China) is acceptable

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulations, and for any other limitation of participation based
             on local regulations.

          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or
             longer if required by local regulation.

          -  Significant illness within two weeks prior to dosing.

          -  A past personal or close family medical history of clinically significant cardiac
             abnormalities

          -  History of Acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease) Clinically significant drug allergy or history of
             atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or
             severe adverse event to darifenacin or similar drugs Any surgical or medical condition
             which might significantly alter the absorption, distribution, metabolism or excretion
             of drugs or which may jeopardize participation in the study Immunodeficiency diseases,
             including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B
             surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse within the
             12 months prior to dosing.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Safety, tolerability, pharmacokinetics, pharmacodynamics, LAF237, vildagliptin, Chinese, healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

